No Data
No Data
Novartis's Fabhalta Trial Success Supports Sales Target -- Market Talk
Express News | Novartis Announced Topline Results From The APPULSE-PNH Phase 3B Study Of Twice-daily Oral Monotherapy Fabhalta (Iptacopan) In Paroxysmal Nocturnal Hemoglobinuria Patients Who Were Switched From Anti-C5 Therapies, After 24 Weeks Of Treatment With...
Novartis' Rare Blood Disorder Drug Improves Hemoglobin Levels in Phase 3b Trial
Kepler Capital Reaffirms Their Buy Rating on Novartis AG (NOVN)
Novartis AG (NOVN) Receives a Hold From Deutsche Bank
US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version
No Data
103827296 : Halo Medan hai hai English understand I'm sorry
72627089 : fractional shares
72627089 : would like to chat about fractional shares
(R-long)103834298 : stop all
l0lBElBgG : k